Menopause Flashcards

1
Q

Define menopause

A

point in time after 12 consecutive months of amenorrhea with no obvious pathologic cause (avg. 52)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Peri-menopause/menopause transition

A

span of time when cycle and endocrine changes occur a few years before and 12 months after final menses resulting from natural menopause

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What age does primary ovarian insufficiency occur?

A
  • less than or equal to age 40, whether natural or induced

- ~1% of women

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is induced menopause?

A

permanent cessation of menses after BSO or iatrogenic ablation of ovarian function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Menopause Physiology

A
  • Loss of follicles, most from atresia, accelerated in our late 30’s
  • Elevated FSH and LH**
  • Ovarian estrogen and inhibin production/feedback decreases
  • Androgen availability increases with age
  • Adrenals decrease DHEA/DHEAS and ovaries decrease androstenedione
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

List the midlife changes

A
  • Changes in bleeding patterns
  • Vasomotor/hot flushes
  • Sleep disturbances
  • Vulvovaginal dryness and discomfort
  • Urinary changes
  • Sexual/decreased libido
  • Cognition concerns
  • Weight gain
  • Skin and hair changes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Routine evaluation

-office exam

A
  • Measured height and weight; BMI or hip/waist ratio
  • BP
  • Pelvic and indicated pap smear
  • Breast exam?
  • Lifestyle concerns
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What breast changes happen in menopause?

A
  • Breasts decrease in size due to less estrogen stimulation
  • Supportive connective tissue decreases
  • Ratio of fat to fibrous tissue increases which makes breasts less firm but easier to evaluate with mammography
  • Increased density considered a risk factor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the colon cancer screening?

A
  • Colonoscopy every 10 years beginning at 50
  • Fecal occult blood testing (FIT, guaiac) yearly
  • Sigmoidoscopy every 5 years; this can be done in combination with FOBT every 5-10 years as an alternative to colonoscopy
  • Barium enema with air contrast every 5 years
  • CT
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What lab screenings should you consider?

A
  • Lipids
  • Chemistry/HbA1c
  • -Fasting glucose, renal/liver function
  • -Test all pregnant women with A1c on first visit
  • TSH
  • Vitamin D
  • STI, HIV, and Hep C as indicated (esp. baby boomers 1946 – 1964)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the frequency of irregular bleeding in menopause?

A
  • 90% of women experience 4-8 years of menstrual cycle changes before menopause
  • Must consider and evaluate for numerous causes, assess risk factors (reproductive tract, systemic, meds)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the main cause of irregular bleeding in menopause?

A

-Main cause is irregular ovulation especially in early perimenopause; lack of ovulation in late perimenopause

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the work-up for irregular bleeding

A

-EMB, ultrasound for endometrial thickness, hysteroscopy, labs, STD screening

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Why hot flashes with menopause?

A
  • Etiology is unclear but could be related to estrogen withdraw, other diseases and medications; also a more narrow thermoneutral zone
  • Average lasts 1-5 minutes; occurs over months to years especially right before and after the LMP
  • Affects up to 75% of women
  • Varies by ethnicity: African American > Hispanics > Caucasian > Asian
  • Increased in obesity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Vasomotor Symptom Treatment

A
  • Treatment of moderate to severe vasomotor symptoms (VMS) remains the primary indication for systemic hormone therapy
  • Hormone therapy is the most successful treatment (a complete list of products available in the US and Canada is on the NAMS website at menopause.org)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What drug is used to treat vasomotor symptoms?

A

Brisdelle 7.5 mg paroxetine approved 2013 for VMS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are the alternative treatments for hot flashes

A
  • Cooler environment
  • Weight loss/exercise
  • Acupuncture
  • Phytoestrogens/soy/isoflavone
  • Black cohash
  • Decrease smoking
  • Vitamin E, omega-3
  • Progesterone
  • Medications used off-label such as Gabapentin, Lyrica, Clonidine, and SSRIs
  • Cognitive behavioral treatment and hypnotherapy have evidence of benefit to decrease bothersome level of symptoms
  • Weight loss and s-equol of soy have evidence of benefit also, though less
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What causes the Genitourinary Syndrome of Menopause (GSM) & vulvavaginal atrophy (VVA)?

A
  • Up to 75% of women have atrophic symptoms

- Lack of estrogen leads to decrease lactobacilli, increased pH, epithelial thinning

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What are the symptoms of genitourinary syndrome of menopause?

A

Ulcerations, petechiae, trauma, pain and dyspareunia can result

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What other etiologies should you rule out for GSM/VVA?

A

Rule out other etiologies such as infection and vulvar dystrophy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What urinary changes are associated with GSM and VVA?

A

Urinary changes include urgency and increased urinary tract infections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the most effective treatment moderate to severe symptoms of vulvar and vaginal atrophy?

A

Estrogen - topical recommended if this is the only indication for estrogen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

How does estrogen treatment improve symptoms?

A

Treatment increases blood flow, epithelial maturity, decreases pH, and increases secretions; urethral benefits of decreased UTIs and urgency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

List the non-prescription treatments for menopause

A
  • Lubricants: usually water-based and used with sexual activity
  • Vaginal moisturizers: used at any time to provide comfort to vaginal tissues
  • Vaginal rejuvenation/laser procedures (in the long run there seems to be more pain issues)
  • Sex
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What other symptoms are relieved with hormonal therapy or local estrogen therapy?

A

dyspareunia, which is a common cause of intercourse avoidance
*hormonal therapy not recommended as sole treatment of other sexual function problems (such as decreased libido)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Should you supplement testosterone for sexual dysfunction?

A

Testosterone does not continue to decline at menopause and limited benefit to supplements

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Which drug can you use for sexual dysfunction in premenopausal women?

A

Flibanserin (Addyi) for treatment of HSDD in premenopausal women

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What is the etiology of breast cancer?

A
  • 1 out of 8 risk in US; 2% of women by age 50

- Most important risk factors are age and gender

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What are the screening tools for breast cancer?

A
  • SBE (self breast exam)
  • mammogram
  • MRI
  • ultrasound
  • ductal lavage
30
Q

What are the potential risks for breast cancer?

A

BRCA gene, personal cancer hx, first degree relative with breast cancer, menarche < 12, menopause > 55, nulliparity or first child after age 30, obesity after menopause, alcohol > 2 drinks/day, lack of exercise, low vitamin D, poor diet, radiation exposure

31
Q

Breast cancer risk reduction

A
  • Lifestyle changes: decrease weight, decrease alcohol
  • Chemoprevention: women at increased risk benefit from SERM treatment to prevent primary breast cancer (ex. tamoxifen and raloxifene)
  • Aromatase inhibitors reduce breast cancer recurrence (anastrazole)
  • Prophylactic mastectomy
32
Q

Explain the relationship between hormone therapy and breast cancer

A
  • *Breast cancer risk increases with estrogen-progestin use beyond 3-5 years**
  • Estrogen only therapy for up to 7 years had no increase on cancer risk
  • No increased risk if wait for 5 years after menopause to start HRT**
  • Unclear if HT risk differs between continuous and sequential progestogen therapy or choice of progestogen
33
Q

Etiology of osteoporosis

A
  • MC bone disorder affecting humans
  • Peak bone mass achieved in third decade
  • 80 % of osteoporosis diagnoses are women
  • 12th leading cause of death in women
34
Q

Relationship between hip fracture and mortality

A

Average age of hip fracture is 82 with 25% increase mortality in the next year

35
Q

Which type of fracture allows you to diagnose osteoporosis?

A

Fragility fracture allows the diagnosis clinically

36
Q

What are the criteria for diagnosis of osteoporosis > 5o years old?

A

DXA measurements include total hip, femoral neck and posterior-anterior lumbar spine and can define the diagnosis with T-score 2.5 SD below the mean

37
Q

What is a T-score?

A

T score is comparison of patient to normal young adult female

38
Q

What is a normal T-score?

A

BMD > or = -1.0

39
Q

What is a low bone mass (osteopenia) T-score?

A

BMD > -2.5 and < -1.0

40
Q

What is a T-score for osteoporosis?

A

BMD < or = to -2.5

41
Q

What is a T-score for severe (established) osteoporosis?

A

BMD < or = -2.5 with h/o fragility fracture

42
Q

List the Osteoporosis Risks

A
  1. Age – increases with age
  2. Genetics – affects peak bone mass
  3. Lifestyle – poor nutrition, smoking, alcohol, decreased activity
  4. Thinness – BMI < 21
  5. Menopausal status – decreases 2% per year during perimenopause
43
Q

What are the bone mineral density testing indications?

A

All women > 65 years old
Postmenopausal with fragility fracture
Postmenopausal <65 years old with one or more risk factor

44
Q

List the postmenopausal <65 years old with one or more risk factor

A
  • Previous fracture after menopause
  • Thinness or BMI < 21
  • Parental hip fracture or family h/o osteoporosis
  • Smoker
  • Rheumatoid arthritis
  • Excessive alcohol intake
  • Long term high risk medications
45
Q

What is the MC fracture type?

A

Vertebral fractures

46
Q

Vertebral fractures etiology

A
  • Often silent
  • Insidious, progressive nature
  • Associated with significant morbidity
  • Predict future spine and hip fractures
  • Associated with 2-fold increase in risk of death
47
Q

What does FRAX calculate?

A

Calculates 10 year risk of major osteoporotic fracture and risk of hip fracture
*Used to guide appropriate patients for therapy

48
Q

What does FRAX use?

A
  • Uses risk factors identified by WHO

- Uses g/cm2 measurement of BMD at femoral neck

49
Q

When does NAMS recommend tx?

A

If postmenopausal with:

  • vertebral or hip fracture
  • BMD diagnosis of osteoporosis
  • osteopenia and FRAX calculator fracture risk of major osteoporotic fx of at least 20% and hip fx of at least 3%
50
Q

What is the daily calcium recommendation?

A

Institute of Medicine recommends 1200 mg daily total from food and supplements for women over 50 to maintain bone health

51
Q

What effects calcium absorption?

A

Absorption affected by estrogen, Vitamin D, foods

52
Q

Relationship between calcium and kidney stones

A

Dietary calcium does not appear to increase kidney stones or risk for CVD

53
Q

What is the importance of vitamin D? Who is deficient?

A
  • Active form mediates the absorption of calcium in the intestines
  • Approximately 50% of the population is thought to be deficient
54
Q

What is the recommended daily dose of vitamin D?

A

~600-1000 IU daily for women

55
Q

List the risk factors for decreased vitamin D levels.

A
  • Increased age
  • Northern climate
  • Limited sun exposure
  • Obesity
  • Poor dietary intake
  • Dark skin
  • Various medical conditions (poor absorption)
56
Q

What is the #1 killer of women?

A

Cardiovascular Disease

57
Q

Relationship between estrogen therapy and cardiovascular disease

A

-ET does not increase the risk of CHD when initiated in women recently menopausal (within 10 years) and may even reduce the risk (age 50-59)
HOWEVER:

*CVD prevention is not an indication for estrogen treatment

58
Q

How does long-term HRT decrease CVD risk?

A

Long term HRT use associated with less accumulation of coronary artery calcium and reduced CHD risk and mortality

59
Q

Relationship between colon cancer and E+P therapy

A

Decreased risk of colon cancer in E+P treated patients

60
Q

Relationship between gallbladder disease and E+P therapy

A
  • Gallbladder disease 2x as frequent in women
  • HRT and OCs increase risk for gallstones with E+P more risk than Estrogen alone and oral HRT has greater risk than transdermal
61
Q

Relationship between menopause and diabetes mellitus

A

Hormonal changes at menopause may contribute to worsening glucose metabolism (relative increase in cortisol) and HT may reduce new onset DM though not approved as prevention
*Glucose metabolism worsens with weight gain and aging

62
Q

What considerations should you make for women with DM starting HRT?

A
  • More risk of CVD in women with DM; statin tx recommended for age 40-75
  • Screening for DM in women age 45 or older (HbA1c, fasting glucose)
63
Q

Relationship between HT and cognition

A
  • Evidence mixed on effect of HT on cognition at time of menopause but overall no negative effects
  • Not recommended at any age for prevention or treatment
  • May increase dementia if begun after age 65
64
Q

What is the therapeutic goal for HRT?

A

Therapeutic goal is lowest effective estrogen dose consistent with individual treatment goals, benefits, and risks plus corresponding low progestogen dose for women with a uterus

65
Q

What dose should you start HRT?

A

Lower doses may be better tolerated and have a more favorable benefit-risk ratio than standard doses

66
Q

What are the benefits of HT??

A
  • May reduce total mortality when initiated soon after menopause (< 10 years); ET and EPT may reduce mortality by 30% in those < 60
  • Women > 60 who had natural menopause at the median age and never used HT should not start without compelling indication/counseling
  • No clear indication that longer HT duration improves or worsens the benefit-risk ratio in postmenopausal women
67
Q

HT in premature/surgical menopause patients

A
  • Use of HT or COC’s for hormone replacement recommended until median age of menopause
  • Women under age 50 likely have smaller risks and greater benefits than women over 50 for same estrogen replacement
68
Q

Relationship between HT and Venous Thromboembolism

A
  • Oral E+P increases risk 2-5 times and ET up to 1.5 times in postmenopausal women
  • Risk emerges soon after therapy began (1-2 years) and decreases over time
69
Q

How can you lower risk for VTE?

A

Possible lower risk with transdermal than oral and lower doses may be safer but no randomized controlled evidence for either

70
Q

What may increase risk of VTE?

A

Synthetic progestins may increase risk compared to natural progesterone

71
Q

List the Venous Thromboembolism risk

A
  • Baseline risk increases with age
  • BMI >30 increases risk 3 fold
  • Other risk factors include immobilization, CVD, thrombophilic disorders, prothrombotic mutations, etc.
  • This is a coagulation event
72
Q

List the Rx Hormone therapy options

A
  • Oral contraceptives
  • Estrogen
  • Progesterone
  • Estrogen/progesterone
  • Agonists/antagonists
  • Androgens